Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > First line maintenance therapy..

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Jun 30, 2023 9:55am

88 Views

Post# 35522077

RE:RE:First line maintenance therapy..

Everybody knows that... I am disapointed with Thera in every possible sense of the word. I'm asking because if they have a first right of refusal (that's a contract) they can make a buck out of it in a bidding war.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security